Does NeoGenomics (NEO) New PTEN CDx Move Reveal a Deeper Precision Oncology Strategy Shift?

Simply Wall St.07-14

In July 2026, NeoGenomics, Inc. launched PTEN IHC CDx, the first FDA-approved immunohistochemistry companion diagnostic for prostate adenocarcinoma, enabling identification of PTEN-deficient tumors in...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2651430120?lang=en_US&edition=fundamental","thumbnail":"https://images.simplywall.st/asset/industry/9551728-choice2-main-header/1585186774276","is_english":true,"pubTime":"2026-07-14 14:29","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2651430120","market":"us","top_or_hot":-1,"title":"Does NeoGenomics (NEO) New PTEN CDx Move Reveal a Deeper Precision Oncology Strategy Shift?","media":"Simply Wall St.","content":"<div>\n<p>In July 2026, NeoGenomics, Inc. launched PTEN IHC CDx, the first FDA-approved immunohistochemistry companion diagnostic for prostate adenocarcinoma, enabling identification of PTEN-deficient tumors in...</p>\n\n<a href=\"https://simplywall.st/stocks/us/healthcare/nasdaq-neo/neogenomics/news/does-neogenomics-neo-new-pten-cdx-move-reveal-a-deeper-preci\">Source Link</a>\n\n</div>\n","source":"simplywall_highlight","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Does NeoGenomics (NEO) New PTEN CDx Move Reveal a Deeper Precision Oncology Strategy Shift?</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nDoes NeoGenomics (NEO) New PTEN CDx Move Reveal a Deeper Precision Oncology Strategy Shift?\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-07-14 14:29 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://simplywall.st/stocks/us/healthcare/nasdaq-neo/neogenomics/news/does-neogenomics-neo-new-pten-cdx-move-reveal-a-deeper-preci><strong>Simply Wall St.</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>In July 2026, NeoGenomics, Inc. launched PTEN IHC CDx, the first FDA-approved immunohistochemistry companion diagnostic for prostate adenocarcinoma, enabling identification of PTEN-deficient tumors in...</p>\n\n<a href=\"https://simplywall.st/stocks/us/healthcare/nasdaq-neo/neogenomics/news/does-neogenomics-neo-new-pten-cdx-move-reveal-a-deeper-preci\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4092","symbol_name":"石油与天然气钻井","start_time":0,"source_url":"https://simplywall.st/stocks/us/healthcare/nasdaq-neo/neogenomics/news/does-neogenomics-neo-new-pten-cdx-move-reveal-a-deeper-preci","article_id":"2651430120","we_media_id":null,"thumbnails":["https://images.simplywall.st/asset/industry/9551728-choice2-main-header/1585186774276"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/healthcare/nasdaq-neo/neogenomics/news/does-neogenomics-neo-new-pten-cdx-move-reveal-a-deeper-preci","rn_cache_url":null,"directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2651430120","pubTimestamp":1784010575,"columns":[],"sourceInfo":{"source_id":"simplywall_highlight","name":"Simply Wall St."},"weMediaInfo":null,"summary":"In July 2026, NeoGenomics, Inc. launched PTEN IHC CDx, the first FDA-approved immunohistochemistry companion diagnostic for prostate adenocarcinoma, enabling identification of PTEN-deficient tumors in patients who may be eligible for AstraZeneca’s TRUQAP (capivasertib), with testing available across its national oncology laboratory network.\nThis test not only extends NeoGenomics’ presence into urologic oncology but also deepens its role in personalized prostate cancer care through rapid,...","collect":0,"end_time":0,"defaultTopTitle":"simplywall.st","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4092":"石油与天然气钻井","LU0106261612.USD":"SCHRODER ISF US SMALLER COMPANIES IMPACT \"A\" ACC","LU0012050646.USD":"SCHRODER ISF US SMALLER COMPANIES IMPACT \"A\" (USD) INC AV","BK4121":"生命科学工具和服务","FBT":"First Trust NYSE Arca Biotechnology Index Fund","NEO":"NeoGenomics","BK4196":"保健护理服务","PTEN":"Patterson-UTI Energy"},"translate_title":"新基因组学（NEO）新的PTEN CDx举措是否揭示了更深层次的精确肿瘤学战略转变？","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"FBT":0.6,"NEO":1.5,"PTEN":1.5},"content_text":"In July 2026, NeoGenomics, Inc. launched PTEN IHC CDx, the first FDA-approved immunohistochemistry companion diagnostic for prostate adenocarcinoma, enabling identification of PTEN-deficient tumors in patients who may be eligible for AstraZeneca’s TRUQAP (capivasertib), with testing available across its national oncology laboratory network. This test not only extends NeoGenomics’ presence into urologic oncology but also deepens its role in personalized prostate cancer care through rapid, integrated molecular workups such as NEO PanTracer Pro. We’ll now explore how this first-of-its-kind PTEN IHC companion diagnostic could reshape NeoGenomics’ investment narrative and growth opportunities. Uncover the next big thing with 20 elite penny stocks that balance risk and reward.AdvertisementNeoGenomics Investment Narrative RecapTo own NeoGenomics, you need to believe its expanding oncology test menu can eventually scale into a more profitable, less volatile business. The PTEN IHC CDx launch reinforces the personalized medicine catalyst in the near term, but it does not remove the key risks around competition, reimbursement, and the company’s history of losses, which still matter more than any single test win. Among recent developments, Medicare MolDX coverage for PanTracer LBx stands out as especially relevant. Together with PTEN IHC CDx and NEO PanTracer Pro, it underscores NeoGenomics’ push to build an integrated tissue and liquid biopsy offering across solid tumors, which could strengthen its NGS positioning but also raises the stakes if new product adoption or pricing falls short of expectations. Yet while the PTEN IHC CDx launch looks promising, investors should also be aware of the ongoing pressure from intensifying competition and... Read the full narrative on NeoGenomics (it's free!)NeoGenomics' narrative projects $982.4 million revenue and $59.9 million earnings by 2029. This requires 9.6% yearly revenue growth and a $159.1 million earnings increase from -$99.2 million today.Uncover how NeoGenomics' forecasts yield a $15.06 fair value, a 7% upside to its current price.Exploring Other PerspectivesNEO 1-Year Stock Price Chart Some of the most optimistic analysts were already assuming revenue could reach about US$1.0 billion and positive earnings by 2029, so this FDA-approved PTEN IHC CDx win may eventually support their view that new companion diagnostics can offset pharma weakness, but it could just as easily prompt you to question how realistic those growth and margin assumptions really are.Explore 2 other fair value estimates on NeoGenomics - why the stock might be worth just $15.06!Form Your Own VerdictDisagree with existing narratives? Extraordinary investment returns rarely come from following the herd, so go with your instincts.A great starting point for your NeoGenomics research is our analysis highlighting 1 important warning sign that could impact your investment decision.Our free NeoGenomics research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate NeoGenomics' overall financial health at a glance.Curious About Other Options?Don't miss your shot at the next 10-bagger. Our latest stock picks just dropped:Explore 26 top quantum computing companies leading the revolution in next-gen technology and shaping the future with breakthroughs in quantum algorithms, superconducting qubits, and cutting-edge research.Capitalize on the AI infrastructure supercycle with our selection of the 52 best 'picks and shovels' of the AI gold rush converting record-breaking demand into massive cash flow.AI is about to change healthcare. These 40 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early.  This article by Simply Wall St is general in nature. We provide commentary based on historical data\n    and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your\n    financial situation. We aim to bring you long-term focused analysis driven by fundamental data.\n    Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.\n    Simply Wall St has no position in any stocks mentioned.Valuation is complex, but we're here to simplify it.Discover if NeoGenomics might be undervalued or overvalued with our detailed analysis, featuring fair value estimates, potential risks, dividends, insider trades, and its financial condition.Access Free AnalysisHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":false,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.46.0","shortVersion":"4.46.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2651430120","isCrawlerRequest":true}